Literature DB >> 10412650

[Plaque stabilization and endothelial protection by cholesterol synthesis inhibitors].

D Müller-Wieland1, M Faust, J Kotzka, W Krone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10412650     DOI： 10.1007/bf03044972

Source DB:  PubMed          Journal:  Herz        ISSN： 0340-9937            Impact factor:   1.443


× No keyword cloud information.
  23 in total

1.  Plasma cholesterol regulates soluble cell adhesion molecule expression in familial hypercholesterolemia.

Authors:  T Sampietro; M Tuoni; M Ferdeghini; A Ciardi; P Marraccini; C Prontera; G Sassi; M Taddei; A Bionda
Journal:  Circulation       Date:  1997-09-02       Impact factor: 29.690

Review 2.  [Cholesterol synthesis inhibitors. Clinical studies on lowering coronary risk and plaque stabilization].

Authors:  D Müller-Wieland; M Faust; W Krone
Journal:  Internist (Berl)       Date:  1998-09       Impact factor: 0.743

Review 3.  Does coronary endothelial dysfunction cause myocardial ischemia in the absence of obstructive coronary artery disease?

Authors:  R O Cannon
Journal:  Circulation       Date:  1997-11-18       Impact factor: 29.690

4.  Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.

Authors:  G O'Driscoll; D Green; R R Taylor
Journal:  Circulation       Date:  1997-03-04       Impact factor: 29.690

5.  Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans.

Authors:  O Tamai; H Matsuoka; H Itabe; Y Wada; K Kohno; T Imaizumi
Journal:  Circulation       Date:  1997-01-07       Impact factor: 29.690

Review 6.  Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points.

Authors:  S Kinlay; A P Selwyn; D Delagrange; M A Creager; P Libby; P Ganz
Journal:  Curr Opin Lipidol       Date:  1996-12       Impact factor: 4.776

7.  Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group.

Authors:  A J van Boven; J W Jukema; A H Zwinderman; H J Crijns; K I Lie; A V Bruschke
Journal:  Circulation       Date:  1996-10-01       Impact factor: 29.690

8.  Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction.

Authors:  L Lacoste; J Y Lam; J Hung; G Letchacovski; C B Solymoss; D Waters
Journal:  Circulation       Date:  1995-12-01       Impact factor: 29.690

9.  The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.

Authors:  T J Anderson; I T Meredith; A C Yeung; B Frei; A P Selwyn; P Ganz
Journal:  N Engl J Med       Date:  1995-02-23       Impact factor: 91.245

Review 10.  Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease.

Authors:  B G Brown; X Q Zhao; D E Sacco; J J Albers
Journal:  Circulation       Date:  1993-06       Impact factor: 29.690
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.